

Recommendations from York and Scarborough Medicines Commissioning Committee May 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Ketamine oral liquid (unlicensed)	Chronic pain	Approved	Requires specialist selection/assessment of complex patients.	Hospital specialist prescribing only for patients who have exhausted other options.	Red	Nil for primary care
Modafinil (Provigil®)	Fatigue associated with multiple sclerosis	Not approved	Updated following NICE clinical guideline (CG186) for MS.	This treatment is decommissioned.	Black	Nil
Verteporfin (Visudyne®) photodynamic therapy	Central serous chorioretinopathy	Not approved	Limited clinical evidence.	Not routinely commissioned.	Black	Nil
Tiotropium 2.5 microgram inhaler (Spiriva Respimat®)	Asthma (as per license)	Not approved	Place in therapy to be considered as part of scheduled asthma treatment pathway review.	Not routinely commissioned.	Black	Nil
Tobramycin nebuliser solution (Tobi®, Bramitob®)	Bronchiectasis	Updated position	Specialist only until the pathway is formally reviewed at MCC.	Hospital specialist prescribing only.	Red	Nil
Colistimethate sodium for nebulisation (Colomycin®, Promixin®)	Bronchiectasis	Updated position	Specialist only until the pathway is formally reviewed at MCC.	Hospital specialist prescribing only.	Red	Nil
Gentamicin for nebulisation	Bronchiectasis	Updated position	Specialist only until the pathway is formally reviewed at MCC.	Hospital specialist prescribing only.	Red	Nil

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Mirena® intrauterine delivery system	Licensed indications	Updated position	Routinely used in primary care	Treatment option for licensed indications	Green	No change